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SUMMARY 
A previous review highlighted the independent prognostic significance of baseline patient-
reported outcomes (PROs) for overall survival (OS) in cancer randomized controlled trials 
(RCTs). In response to methodological limitations of studies included, recommendations were 
published in order to promote higher methodological rigour in prognostic factor studies. Our 
systematic review aimed to provide an update and assess whether the methodological quality of 
prognostic factor analyses has changed over time. Of the 44 studies published between 2006 and 
2018 that were included in this review, more standardization and rigour were found. Most trials 
reported at least one PROs domain as independently prognostic. The most common factors 
reported were physical functioning (PF) (39%; 17/44) and global health/QoL (GHQ) (36%; 
16/44). These findings highlight their value as prognostic or stratification factors in research 
across the majority of cancer types.  
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BACKGROUND 1 
Historically, prognostic models for survival in cancer have employed well-established clinician-2 
reported criteria, such as performance status (PS), age, and tumour stage as the main factors of 3 
interest, placing little to no emphasis on patient-reported outcomes (PROs) (1,2). A growing 4 
body of work, however, shows that the incorporation of PROs in cancer care is crucial, as it 5 
allows for increased focus and more accurate information on issues that matter to patients (3).  6 
Over the course of the past three decades, the importance of the patient perspective has been 7 
increasingly recognized. That has led to more frequent assessment of PROs in clinical practice as 8 
well as in randomized controlled trials (RCTs) making these data more easily available for 9 
prognostic model building. There is also evidence demonstrating the growing importance of 10 
baseline PROs as independent prognostic factors for overall survival (OS). A landmark 11 
systematic review by Gotay et al. (4) including 39 publications published between 1989 and 12 
2006 and involving 13,874 patients, found that baseline patient-reported physical functioning 13 
(PF) (28%; 11/39) and global health status/quality of life (QoL) (GHQ) (38; 15/39) 14 
independently predicted OS in the majority of cancer types (4). The additional prognostic 15 
significance of PF was supported by a meta-analysis of 10,108 patients (5).  16 
Despite these data supporting the added prognostic value of PROs, researchers and clinicians still 17 
face challenges to complement clinical and survival based endpoints with PROs. Their use as 18 
prognostic factors in clinical practice is limited when it comes to daily assessment, detection of 19 
high risk patients and decision-making (6), undermining the systematic use of the patient 20 
perspective during the diagnostic process (7). Their integration in RCTs as stratification factors 21 
is also rare. 22 
Hence, this review aimed to update Gotay et al.¶V (4) review and focused on prognostic factor 23 
publications from 2006 to 2018. The review builds upon its results by examining the extent to 24 
which previously reported and possibly new PROs show prognostic value across different cancer 25 
types. In response to the methodological inconsistencies in studies included in Gotay et al.¶V (4) 26 
review, an evaluation of prognostic factor analysis and methods was undertaken by Mauer et al. 27 
(8). This evaluation led to the creation of recommendations aimed at improving the 28 
methodological quality of future prognostic factor studies. Therefore, the second aim of our 29 
study was to assess the implementation of analysis methods and to evaluate the methodological 30 
rigour of prognostic factor analysis in recent studies.31 
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 32 
Data collection 33 
Search strategy and selection criteria 34 
A systematic literature review was conducted following the general Cochrane methodology as 35 
noted in the Handbook for Systematic Reviews of Interventions (9), and adhering to PRISMA 36 
guidelines ensuring transparent and complete reporting (10,11).  37 
MEDLINE searches were undertaken with the aim of gathering studies on cancer RCTs 38 
published in English between 2006 and 2018. The key words used were ³FDQFHU´³SURJQRVWLF´, 39 
and ³TXDOLW\ RI OLIH´. Other PRO related terms were also specified: ³GHSUHVVLRQ´ ³DQ[LHW\´40 
³IDWLJXH´³EDVHOLQHSDLQ´ and commonly-used PRO instruments (³&(6-'´³%',´³4/4-&´41 
³67$,´ ³56&/´ ³3$,6´ ³+$'6´ ³%3,´ ³06$6´ ³SDLQ DVVHVVPHQW´ ³IXQFWional 42 
DVVHVVPHQW´ ³)$&7 TXHVWLRQQDLUH´ ³)$&7 VXUYH\´ ³)/,&´ and ³VHOI-UDWHG KHDOWK´). In 43 
addition to MEDLINE searches, reference searches of selected papers were undertaken and 44 
experts in the field were consulted to help identify additional studies. All studies selected 45 
included prospective phase II, III or IV cancer RCTs; at least one PRO baseline assessment using 46 
single (e.g., pain) or multidimensional outcomes (e.g., GHQ); and at least one multivariable 47 
analysis examining the relationship between baseline PROs and OS/mortality, while controlling 48 
for cancer-related and/or sociodemographic factors. Our exclusion criteria omitted any RCTs that 49 
evaluated psychological or supplementary interventions and all publications already included in 50 
*RWD\HW DO¶V Ueview, to avoid redundancy (4). Supplementary treatments were defined as any 51 
other interventions that did not include anti-cancer therapy and were not purely psychological 52 
interventions (e.g., nutritional counselling). Literature reviews and conference abstracts were 53 
also excluded. Whereas Gotay et al. (4) included all types of prognostic factor studies, we 54 
restricted our review to RCTs only, recognized as the gold standard due to their increased 55 
methodological as well as statistical rigour and minimization of bias and confounding factors. 56 
All study characteristics and results were reviewed by two independent reviewers (JM and CP, 57 
MP or FM) who also critically assessed the prognostic factor analysis of each paper. In case of 58 
disagreements, a third person was consulted to reach a consensus (CP, MP or FM).  59 
The methodological evaluation focused on the criteria suggested by Mauer et al. (8) and included 60 
sample size, missing data, selection of predictors, model building, predictive accuracy and model 61 
validation. The fulfilment of these criteria was assessed by two independent assessors and 62 
compared to the prior review in a descriptive manner. All criteria are detailed inTables 1 and 4. 63 
INSERT TABLE 164 
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 65 
Findings 66 
Study characteristics: 67 
The search identified 1,803 publications. Forty-four studies met all inclusion criteria for review 68 
(Figure 1).  69 
INSERT FIGURE 1  70 
This review includes findings from phase II or III  RCTs summarizing results from 28,281 71 
patients across 13 cancer types, including lung (20%; 9/44), head and neck (14%; 6/44), 72 
pancreatic (11%; 5/44), ovarian (11%; 5/44), colorectal (7%; 3/44), prostate (7%; 3/44), 73 
esophageal (7%; 3/44), brain (7%; 3/44), liver (4%; 2/44), breast (4%; 2/44), gastric (2%; 1/44), 74 
myeloma (2%; 1/44) and melanoma (2%; 1/44). Most studies targeted advanced or metastatic 75 
stages of the disease (75%; 33/44). Sample sizes ranged from 63 to 1,152 patients, and 23,122 76 
cancer patients who completed PROs assessments were included in total. The main PRO tools 77 
used to assess these patients were the EORTC Quality of Life Core Questionnaire (QLQ-C30) 78 
(50%; 22/44) and the Functional Assessment of Cancer Treatment (FACT) questionnaire (37%; 79 
16/44). The main study characteristics and prognostic factor results are summarized in Table 2 80 
(1,12-54).  81 
INSERT TABLE 2 82 
Clinical factor assessment: 83 
All the studies reported controlling for various clinical factors. PS was the most commonly used 84 
clinical factor (86%; 38/44). Treatment arm (45%; 20/44), disease stage (34%; 15/44), serum 85 
markers (32%; 14/44) and tumor size (23%; 10/44) were also used. Several studies confirmed the 86 
prognostic significance of PS (39%; 15/38) and treatment arm (50%; 10/20). Some publications 87 
(25%; 11/44) failed to report the prognostic value of any clinical factors. 88 
Main PRO factors: 89 
In the majority of studies (93%; 41/44), at least one PRO domain was significantly associated 90 
with OS (p < .05) after controlling for other clinical variables. The most commonly reported 91 
independent prognostic factors were PF (39%; 17/44) and GHQ (36%; 16/44), in nine and eight 92 
cancer types, respectively, and the most frequently reported prognostic symptom was pain (16%; 93 
7/44). The majority of the studies that reported PF (71%; 12/17) and GHQ as prognostic factors 94 
(75%; 12/16) involved patients with advanced or metastatic stages of disease. However, the C-95 
indices indicated only a small prognostic improvement when adding these PROs to the other 96 
clinical factors (see p. 19). The prognostic significance of PF was mainly reported using the 97 
EORTC QLQ-C30 (53%; 9/17), or FACT tools (29%; 5/17). Similarly, GHQ was found to be 98 
prognostic for OS in 31% (5/16) of the papers. All identified PRO domains found to be 99 
prognostic are listed in Table 3. Some similarities in prognostic significance were found in 100 
studies involving specific cancer types such as lung (20%; 9/44), ovarian (11%; 5/44) and 101 
prostate (7%; 3/44). In lung, PF (44%; 4/9) and GHQ (67%; 6/9) were prognostic, mainly 102 
separately. Both of these domains were also prognostic factors in ovarian cancer (60%; 3/5). All 103 
three papers including prostate cancer patients reported pain as a prognostic factor. However, 104 
such trends were not found in all studies and some presented surprising results. In one brain 105 
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study, lower social functioning (28) was associated with longer survival while in another brain 106 
study, lower emotional functioning and more communication deficits were related to longer 107 
survival (29).  108 
Only three studies (7%; 3/44) found no relationship between PROs and OS. Of these, two 109 
involved advanced head & neck cancer patients (17,38) and one included esophageal cancer 110 
patients in stages I-IV (44). 111 
INSERT TABLE 3 112 
Methodological evaluation: 113 
None of the studies followed all of the recommendations proposed by Mauer et al. (8), yet all 114 
fulfilled at least three out of 20 subcriteria. The vast majority of the studies satisfied two 115 
requirements: sample size (93%; 41/44) and model building strategy through use of Cox 116 
Proportional Hazards (PH) models (95%; 42/44). Other subcriteria such as reporting of patient 117 
characteristics with valid PRO assessment (66%; 29/44), a priori selection of PRO predictors 118 
(54%; 24/44) and univariate analyses reporting were commonly met. However, some subcriteria 119 
were not systematically reported. The description of missing data (11%; 5/44), the a priori 120 
definition of a hypothesis (11%; 5/44), the verification of assumptions in the models (20%; 9/44) 121 
and the use of external validation (4%; 2/44) were generally limited. Also, despite the 122 
importance of quantifying predictive accuracy, only 32% of papers (14/44) reported this 123 
measurement. Among these papers, 78% (11/14) reported limited improvement of the predictive 124 
accuracy. Moreover, while the use of continuous variables was recommended (8), categorical 125 
variables were regularly used (32%; 14/44), often with predefined categories (64%; 9/14). The 126 
use of interactions was discouraged by Mauer et al. (8) and most publications did not report 127 
including them in their analyses (86.4%; 38/44). Table 4 summarizes the results of the 128 
methodological evaluation of the current review (8). A list of the 44 included studies with the 129 
full methodological assessment is provided in the appendices (p. 19).  130 
INSERT TABLE 4131 
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 132 
DISCUSSION 133 
The aim of this study was to update the review by Gotay et al. (4) and provide a critical analysis 134 
of the methodology reported in the papers included, based on work by Mauer et al. (8). For this 135 
purpose, we systematically appraised prognostic factor results from cancer RCTs (n= 44) 136 
published since the prior review. Prognostic factor results from cancer RCTs (n= 44) were 137 
compared and found to be similar in many regards with those reported in the review by Gotay et 138 
al. (4) (current review vs. Gotay et al.¶V review): most studies were based on advanced or 139 
metastatic cancer patients (77%; 34/44 vs. 61.5%; 24/39), most frequently involving lung cancer 140 
patients (20.4%; 9/44 vs. 30.8%; 12/39). Studies were mainly phase III RCTs (75%; 33/44 vs. 141 
74%; 29/39) and assessed PROs in most patients (n= 23,122 vs. n= 13,874) using the EORTC 142 
QLQ-C30 (50%; 22/44 vs. 56%; 22/39) (55). This instrument has been reported as one of the 143 
most widely-used tools to assess cancer patientV¶ subjective well-being in the literature (56±59).  144 
First, we examined the extent to which previously reported and new PROs showed prognostic 145 
value. The findings from both reviews showed that the majority of RCTs (93.2%; 41/44 vs. 146 
92.3%; 36/39) reported at least one PRO domain which was prognostic of OS. The most 147 
commonly reported independent prognostic factors were PF (38.6%; 17/44 vs. 28.2%; 11/39) 148 
and GHQ (36.4%; 16/44 vs. 38.5%; 15/39) with, however, limited added value. These domains 149 
were prognostic mainly in advanced stages of the disease, which is consistent with the high 150 
number of studies targeting these stages only. Other PRO domains such as pain were found to be 151 
prognostic of OS in seven studies.  152 
Additional evidence also supports the prognostic significance of specific PROs such as PF and 153 
GHQ. A relationship between PF and survival time has been shown in a number of studies (60±154 
64) and in a meta-analysis of 10,108 cancer patients (5). GHQ has also been associated with OS 155 
in different cancer types, highlighting its prognostic value (63,65±68). These associations 156 
suggest that prognosis and, by extension, its prediction could be slightly improved by integrating 157 
PF and GHQ into prognostic models. This evidence also supports the importance of evaluating 158 
PROs when providing information regarding FDQFHUSDWLHQWV¶prognoses. 159 
Despite the considerable overlap in findings between Gotay et al.¶V review (1989-2006) (4) and 160 
the current results (2006-2018), there were some differences that merit discussion. Although both 161 
reviews identified three studies which did not find any prognostic PRO domains, in Gotay et al.¶V 162 
review (4), all of these studies involved early breast cancer patients, which led the authors to 163 
suggest that prognostic factors might be more relevant for advanced disease stages. In the current 164 
review, the studies (17,38,44) that did not find evidence of prognostic value for PROs involved 165 
head and neck cancer patients in an advanced stage of the disease (17,38) and esophageal cancer 166 
patients in stages I-IV (44). This indicates that an advanced disease setting alone may not be a 167 
sufficient condition for finding prognostic significance of PROs. The authors of these studies 168 
hypothesized that methodological issues such as missing data could help to account for the lack 169 
of added prognostic value (38,44), suggesting that this may be better demonstrated in more 170 
rigorously designed trials. Furthermore, one of these publications assessed the prognostic value 171 
of emotional functioning only, which is a significant limitation, given little evidence to suggest 172 
that emotional functioning is a prognostic factor for OS.  173 
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A further difference between the findings in both reviews concerns the PRO domains which were 174 
found to be prognostic of OS. Although PF and GHQ remained the most common prognostic 175 
factors in both reviews, other PRO domains were less consistently reported. This may be 176 
explained by the variety of methods used to conduct the prognostic studies in terms of PRO 177 
instruments and clinical data collection. Indeed, some of these assessed multidimensional aspects 178 
of QoL while others were more focused on specific symptoms. Moreover, between these tools, 179 
the level of difference in scores may be captured using different approaches (e.g., a 10-point 180 
versus a 100-point underlying scale). These factors, combined with the different cancer types 181 
investigated, may help to account for some of the differences between both reviews. Insofar as 182 
symptoms are very trial-dependent, linked to the treatment under investigation, it is not 183 
surprising that they are less often prognostic. In contrast, PF and GHQ are relevant across a wide 184 
array of treatment modalities and disease sites. Pain was the most frequently reported prognostic 185 
symptom, which reflects its association with many different disease sites and treatments (69). In 186 
some clinical contexts, pain may be an underlying sign of more advanced disease and infiltrative 187 
growth (70), and it is possible that such patient-reported symptom information could be more 188 
sensitive during specific stages than what might be observed in a medical imaging scan, for 189 
instance. This may account for the added prognostic value of pain, in particular.   190 
The more stringent inclusion criteria applied in the current review, which included RCTs only, 191 
may also account for differences between reviews. Since RCTs minimize potential bias and 192 
confounding factors, they provide a more robust context for the identification of prognostic 193 
significance in PROs. However, the trials nevertheless present some limitations which should be 194 
considered. For example, the low number of publications including patients in earlier disease 195 
stages makes it difficult to draw conclusions about stage-dependent prognostic significance. 196 
Moreover, although a large number of studies reported significant findings, this may reflect 197 
publication bias. 198 
Our second aim, to undertake a methodological evaluation of the studies reviewed, showed that 199 
none of the studies followed Mauer et al.¶V (8) recommendations completely and only 20.4% 200 
(9/44) implemented at least half of the criteria. However, at least three subcriteria were fulfilled 201 
per study and most of the key methodological issues were improved relative to the Mauer et al. 202 
(8) review. Several criteria, such as forced inclusion of clinical factors in the model building 203 
strategy and verification of the PH assumption, were reported less frequently in our review. 204 
Although the methodological evaluation performed in our review showed that prognostic factor 205 
analyses are improving, their implementation is still neither standardized nor systematically 206 
reported. For example, whereas most of the studies reported hazard ratios, two of them reported 207 
odds ratios. Also, some studies failed to report confidence intervals, which are needed for 208 
accurate interpretation. This inconsistent reporting complicates comparison between trials and 209 
interpretation of the prognostic findings, making it hard to draw strong conclusions and 210 
accurately assess the magnitude of effects. 211 
This lack of rigour and standardization remains a common challenge (71) particularly insofar as 212 
clinical relevance is often not addressed. The reporting and interpretation of prognostic findings 213 
in both reviews was mainly based on statisticaly significant findings without clearly pre-defining 214 
what would be considered as clinically relevant. It is difficult to assess the magnitude of effect 215 
when so many different model-fitting techniques are used and information on model-building 216 
strategies is ommitted. The comparison of clinical versus PRO factors is further complicated by 217 
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the fact that both outcomes have different underlying measurement properties. While an increase 218 
or decrese of one point may be significant for PS, what is the equivalent level of change in 219 
patient-reported PF? These sorts of differences, combined with the different instruments used to 220 
assess PROs between studies, make it harder to draw concrete conslusions concerning the 221 
strengh of association for PROs versus clinical factors. It seems, therefore, that recommendations 222 
such as those proposed by Mauer et al. (8) are not sufficient to improve the quality of reporting. 223 
This may also be due, in part to limited visibility of Mauer et al¶V UHFRPPHQGDWLRQV 224 
combined with the fact that some of the studies included were conducted or analyzed before its 225 
publication. 226 
Taken together, 83 studies from the past 30 years have provided evidence for prognostic 227 
significance of PROs, and specifically PF and GHQ. This suggests that these PROs should be 228 
integrated into clinical cancer research and care, given the additional prognostic information they 229 
provide. In daily practice, this information could be used when communicating with patients, to 230 
provide a more comprehensive and patient-centric description of their symptoms and 231 
functioning, and to help inform decisions regarding treatment choices (7). In terms of research, 232 
PROs could be included as stratification factors to complement other clinical factors in RCTs in 233 
which survival is a primary endpoint, PROs are included as an endpoint, and where relevant 234 
PROs have been identified as prognostic factors. Such stratification may help provide a more 235 
accurate interpretation of studies' outcomes in future clinical trials (21). In palliative research, 236 
information on the prognostic value of PROs may be especially important, given the need to 237 
minimize unwanted symptoms and side effects in an especially at-risk population. 238 
Despite the promising findings confirming the prognostic significance of PH and GHQ, which 239 
suggests that these PROs may be the most eligible candidates for stratification, the limited 240 
statistical evidence for the increased predictive accuracy of PROs as well as the complexity 241 
surrounding the assessment of magnitude of effects, suggests that more quantitative work is 242 
required to better understand how and in which clinical settings PROs should be used for 243 
stratification. Such quantitative work would extend beyond descriptive reporting in reviews and 244 
would require patient-level data, as demonstrated in previously published meta-analyses (72). 245 
This would facilitate the creation of categories of PRO scores to promote accurate statistical and 246 
clinical interpretation. A meta-analysis generating standardized thresholds would represent a 247 
major step forward for patient risk-assessment. Moreover, a higher level of transparency and 248 
standardization in prognostic factor studies is needed, in order to more accurately compare and 249 
summarize results. Having more carefully defined clinical groups and contexts would also help 250 
to determine in which specific settings PROs are independently prognostic. Such specification 251 
could help to clarify when, for example, more specific symptoms (e.g., pain) are prognostic. 252 
Future prognostic studies should also report both statistical and clinical significance in order to 253 
better capture the magnitude of effects, which would allow for a more precise estimate of 254 
prognostic value.  255 
The current research climate is moving towards greater standardization in all phases of PRO 256 
research, with various initiatives such as the Standard Protocol Items: Recommendations for 257 
Interventional Trials (SPIRIT-PRO) (73), CONsolidated Standards of Reporting Trials-Patient-258 
Reported Outcomes Statement (CONSORT-PRO) (74), Setting International Standards in 259 
Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) 260 
Consortium (75), and the recent guidelines for systematic review and meta-analysis of prognostic 261 
factor research by Riley and colleagues (76). Having more standardized and widely disseminated 262 
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prognostic factor analysis guidelines would allow for more rigorous evaluation of the prognostic 263 
importance of PROs for OS, thereby facilitating their use in both research and practice.  264 
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